๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Carcinoma, Squamous Cell

Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC) NCT07627347NA1 site๐Ÿ“ Guangzhou Nanfang Hospital, Southern Medical University ยท Tests: anlotinib+bevacizumab Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC NCT05941338Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Tirelizumab ,+Carboplatin+albumin-bound paclitaxel VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites๐Ÿ“ Santa Rosa๐Ÿ“ Hartford๐Ÿ“ Washington D.C. VM Oncology, LLC ยท Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111Phase 1, Phase 252 sites๐Ÿ“ Pittsburgh๐Ÿ“ Natal๐Ÿ“ Porto Alegre Merck Sharp & Dohme LLC ยท Tests: Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU) Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma NCT06606028n/a1 site๐Ÿ“ San Francisco University of California, San Francisco ยท Tests: Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC NCT05738434Phase 21 site๐Ÿ“ Zhengzhou The First Affiliated Hospital of Zhengzhou University ยท Tests: Camrelizumab+Apatinib+Chemotherapyโ†’Camrelizumab+Apatinib, Camrelizumab+Chemotherapyโ†’Camrelizumab Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma NCT05937438Phase 1, Phase 21 site๐Ÿ“ Hefei Anhui Provincial Hospital ยท Tests: Immune Checkpoint Inhibitors Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) NCT04807140Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Toripalimab, nab-paclitaxel, carboplatin, Toripalimab, Surgical resection A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ Columbus Tanabe Pharma America, Inc. ยท Tests: MT-4561 Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis NCT07029152NA8 sites๐Ÿ“ Bruges๐Ÿ“ Brussels๐Ÿ“ Brussels Universitair Ziekenhuis Brussel ยท Tests: Anal smear, Self-administered questionnaire, EQ-5D-5L questionnaire, High Resolution Anoscopy (HRA) Intra-lesional Tumor Boost for Bulky Cervical Cancer NCT07435376Phase 21 site๐Ÿ“ Seongnam-si Seoul National University Bundang Hospital ยท Tests: intra-lesional boost IMRT, High Dose Rate Brachytherapy A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma NCT06843889Phase 21 site๐Ÿ“ Guangzhou Nanfang Hospital, Southern Medical University ยท Tests: Toripalimab (240mg day1, Q3W*3cycle) Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers NCT05553782EARLY Phase 12 sites๐Ÿ“ Boston๐Ÿ“ Boston Brigham and Women's Hospital ยท Tests: Implantable Microdevice (IMD) Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) NCT07485296Phase 21 site๐Ÿ“ Rozzano Gruppo Oncologico del Nord-Ovest ยท Tests: Postbiotix-HLAโ„ข is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic., placeโ€ฆ Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma NCT06476067n/a2 sites๐Ÿ“ Nagoya๐Ÿ“ Chลซล City of Hope Medical Center ยท Tests: Surgery A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer NCT06385080Phase 1, Phase 256 sites๐Ÿ“ La Jolla๐Ÿ“ Aurora๐Ÿ“ New Haven Janssen Research & Development, LLC ยท Tests: Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers NCT04747054Phase 326 sites๐Ÿ“ Avignon๐Ÿ“ Besanรงon๐Ÿ“ Bordeaux UNICANCER ยท Tests: Pembrolizumab, Loco-regional radiotherapy, Chemotherapy Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus NCT05918510n/a1 site๐Ÿ“ Rome Regina Elena Cancer Institute ยท Tests: Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology NCT05756569Phase 24 sites๐Ÿ“ Atlanta๐Ÿ“ Atlanta๐Ÿ“ Atlanta Emory University ยท Tests: Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-ฮณ Expression and CTM Correlation With DS-SACA Chip NCT06678724n/a1 site๐Ÿ“ Zhubei National Taiwan University Hospital T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer NCT02133196Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy NCT06494995Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: Cadonilimab, Low-dose radiotherapy, SBRT, Capecitabine STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision NCT06358469NA12 sites๐Ÿ“ Kelowna๐Ÿ“ Vancouver๐Ÿ“ Victoria Canadian Cancer Trials Group ยท Tests: Surgery, Active Surveillance Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: Nimotuzumab, Tegafur, radiotherapy A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) NCT07863141Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: anlotinib + PD-1 inhibitor, PD-1 inhibitor Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC NCT06876844Phase 21 site๐Ÿ“ Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaโ€ฆ ยท Tests: combination of Surufatinib and Envolizumab A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764Phase 274 sites๐Ÿ“ Washington D.C.๐Ÿ“ Athens๐Ÿ“ Lexington Bristol-Myers Squibb ยท Tests: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Whittier Daiichi Sankyo ยท Tests: Ifinatamab deruxtecan Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma NCT06567314Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Ivonescimab A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors NCT07814248Phase 13 sites๐Ÿ“ Maumee๐Ÿ“ Portland๐Ÿ“ Fairfax TwoStep Therapeutics, Inc. ยท Tests: TS-104
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy